Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: Applications for oral infections

Journal of Dental Research

Volumn 84, Issue 12, 2005, Pages 1104-1116

  Hajishengallis, G ^a,d   Arce, S ^b,c   Gockel, C M ^b,c   Connell, T D ^b,c   Russell, M W ^b,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Adjuvant; Cholera toxin; Heat labile enterotoxin; Immune response; Vaccine

Indexed keywords

ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT;

ANIMAL; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MUCOSAL IMMUNITY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ENTEROTOXINS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOTHERAPY;

EID: 33644815406     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910508401205     Document Type: Review

References (156)

1. Ågren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY (1999). Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol 162:2432-2440.
2. Åhrén C, Jertborn M, Svennerholm A-M (1998). Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood. Infect Immun 66:3311-3316.
3. Akira S, Takeda K (2004). Toll-like receptor signalling. Nat Rev Immunol 4:499-511.
4. Aman AT, Fraser S, Merritt EA, Rodigherio C, Kenny M, Ahn M, et al. (2001). A mutant cholera toxin B subunit that binds GM1-ganglioside but lacks immunomodulatory or toxic activity. Proc Natl Acad Sci USA 98:8536-8541.
5. Arce S, Nawar H, Russell MW, Connell TD (2005). Differential binding of Escherichia coli enterotoxins LT-IIa, LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation in lymphoid cells. Infect Immun 73:2718-2727.
6. Arpin C, Déchanet J, Van Kooten C, Merville P, Grouard G, Brière F, et al. (1995). Generation of memory B cells and plasma cells in vitro. Science 268:720-722.
7. Asanuma H, Aizawa C, Kurata T, Tamura S (1998). IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration. Vaccine 16:1257-1262.
8. Bagley KC, Abdelwahab SF, Tuskan RG, Lewis GK (2003). An enzymatically active A domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect Immun 71:6850-6856.
9. Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA (2000). Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J Immunol 165:6454-6462.
10. Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, et al. (1997). A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 94:4610-4614.
11. Black CA, Rohan LC, Cost M, Watkins SC, Draviam R, Alber S, et al. (2000). Vaginal mucosa serves as an inductive site for tolerance. J Immunol 165:5077-5083.
12. Braun MC, He JP, Wu CY, Kelsall BL (1999). Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor b1 and b2 chain expression. J Exp Med 189:541-552.
13. Bromander A, Holmgren J, Lycke N (1991). Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol 146:2908-2914.
14. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, et al. (2003). Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 171:1684-1690.
15. Challacombe SJ, Tomasi TB (1980). Systemic tolerance and secretory immunity after oral immunization. J Exp Med 152:1459-1472.
16. Clemens JD, van Loon F, Sack DA, Chakraborty J, Rao MR, Ahmed F, et al. (1991). Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis 163:1235-1242.
17. Clements JD (1990). Construction of a nontoxic fusion peptide for immunization against Escherichia coli strains that produce heat-labile and heat-stable enterotoxins. Infect Immun 58:1159-1166.
18. Cong Y, Weaver CT, Elson CO (1997). The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J Immunol 159:5301-5308.
19. Connell TD, Metzger DJ, Wang M, Jobling MG, Holmes RK (1995). Initial studies of the structural signal for extracellular transport of cholera toxin and other proteins recognized by Vibrio cholerae. Infect Immun 63:4091-4098.
20. Connell TD, Metzger D, Sfintescu C, Evans RT (1998). Immunostimulatory activity of LT-IIa, a type II heat-labile enterotoxin of Escherichia coli. Immunol Lett 62:117-120.
21. Critchley DR, Magnani JL, Fishman PH (1981). Interaction of cholera toxin with rat intestinal brush border membranes. Relative roles of gangliosides and galactoproteins as toxin receptors. J Biol Chem 256:8724-8731.
22. Czerkinsky C, Russell MW, Lycke N, Lindblad M, Holmgren J (1989). Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun 57:1072-1077.
23. Dertzbaugh MT, Elson CO (1993). Reduction in oral immunogenicity of cholera toxin B subunit by N-terminal peptide addition. Infect Immun 61:384-390.
24. Dertzbaugh MT, Peterson DL, Macrina FL (1990). Cholera toxin B-subunit gene fusion: structural and functional analysis of the chimeric protein. Infect Immun 58:70-79.
25. Elson CO, Dertzbaugh MT (2005). Mucosal adjuvants. In: Mucosal immunology. 3rd ed. Mestecky J, Bienenstock J, Lamm ME, Mayer L, Strober W, McGhee JR, editors. San Diego: Elsevier/Academic Press, pp. 967-986.
26. Elson CO, Holland SP, Dertzbaugh MT, Cuff CF, Anderson AO (1995). Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J Immunol 154:1032-1040.
27. Finkelstein RA, Burks MF, Zupan A, Dallas WS, Jacob CO, Ludwig DS (1987). Epitopes of the cholera family of enterotoxins. Rev Infect Dis 9:544-561.
28. Fishman PH (1986). Recent advances in identifying the functions of gangliosides. Chem Phys Lipids 42:137-151.
29. Francis ML, Ryan J, Jobling MG, Holmes RK, Moss J, Mond JJ (1992). Cyclic AMP-independent effects of cholera toxin on B cell activation. II. Binding of ganglioside GM1 induces B cell activation. J Immunol 148:1999-2005.
30. Fraser SA, de Haan L, Hearn AR, Bone HK, Salmond RJ, Rivett AJ, et al. (2003). Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functions. Infect Immun 71:1527-1537.
31. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, et al. (1995). B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523-532.
32. Frendéus B, Wachtler C, Hedlund M, Fischer H, Samuelsson P, Svensson M, et al. (2001). Escherichia coli P fimbriae utilize the Toll-like receptor 4 pathway for cell activation. Mol Microbiol 40:37-51.
33. Freytag LC, Clements JD (1999). Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol 236:215-236.
34. Fujinaga Y, Wolf AA, Rodighiero C, Wheeler H, Tsai B, Allen L, et al. (2003). Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulum. Mol Biol Cell 14:4783-4793.
35. Fukuta S, Magnani JL, Twiddy EM, Holmes RK, Ginsburg V (1988). Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LTIIa, and LTIIb. Infect Immun 56:1748-1753.
36. Gill DM, Clements JD, Robertson DC, Finkelstein RA (1981). Subunit number and arrangement in Escherichia coli heat-labile enterotoxin. Infect Immun 33:677-682.
37. Gockel CM, Russell MW (2005). Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein. Immunology (in press).
38. Gockel CM, Bao SS, Beagley KW (2000). Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol Immunol 37:537-544.
39. Guidry JJ, Cárdenas L, Cheng E, Clements JD (1997). Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect Immun 65:4943-4950.
40. Guth BE, Pickett CL, Twiddy EM, Holmes RK, Gomes TA, Lima AA, et al. (1986). Production of type II heat-labile enterotoxin by Escherichia coli isolated from food and human feces. Infect Immun 54:587-589.
41. Hajishengallis G, Nikolova E, Russell MW (1992). Inhibition of Streptococcus mutans adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A (S-IgA) antibodies to cell surface protein antigen I/II: reversal by IgA1 protease cleavage. Infect Immun 60:5057-5064.
42. Hajishengallis G, Hollingshead SK, Koga T, Russell MW (1995). Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 154:4322-4332.
43. Hajishengallis G, Harokopakis E, Hollingshead SK, Russell MW, Michalek SM (1996a). Construction and oral immunogenicity of a Salmonella typhimurium strain expressing a streptococcal adhesin linked to the A2/B subunits of cholera toxin. Vaccine 14:1545-1548.
44. Hajishengallis G, Michalek SM, Russell MW (1996b). Persistence of serum and salivary antibody responses after oral immunization with a bacterial protein antigen genetically linked to the A2/B subunits of cholera toxin. Infect Immun 64:665-667.
45. Hajishengallis G, Russell MW, Michalek SM (1998). Comparison of an adherence domain and a structural domain of Streptococcus mutans antigen I/II in protective immunity against dental caries in rats after intranasal immunization. Infect Immun 66:1740-1743.
46. Hajishengallis G, Nawar H, Tapping RI, Russell MW, Connell TD (2004). The type II heat-labile enterotoxins LT-IIa and LT-IIb and their respective B pentamers differentially induce and regulate cytokine production in human monocytic cells. Infect Immun 72:6351-6358.
47. Hajishengallis G, Tapping RI, Martin MH, Nawar H, Russell MW, Connell TD (2005). Toll-like receptor 2 mediates cellular activation by the B subunits of type II heat-labile enterotoxins. Infect Immun 73:1343-1349.
48. Hammond SA, Walwender D, Alving CR, Glenn GM (2001). Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 19:2701-2707.
49. Hannun YA, Linardic CM (1993). Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids. Biochim Biophys Acta 1154:223-236.
50. Harokopakis E, Hajishengallis G, Greenway TE, Russell MW, Michalek SM (1997). Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of co-expressed cholera toxin A2/B subunits. Infect Immun 65:1445-1454.
51. Harrod T, Martin M, Russell MW (2001). Long-term persistence and recall of immune responses in aged mice after mucosal immunization. Oral Microbiol Immunol 16:170-177.
52. Hasbold J, Hong JS, Kehry MR, Hodgkin PD (1999). Integrating signals from IFN-γ and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a. J Immunol 163:4175-4181.
53. Holmes RK, Twiddy EM, Pickett CL, Marcus H, Jobling MG, Petitjean FMJ (1990). The Escherichia coli/Vibrio cholerae family of enterotoxins. In: Symposium on molecular mode of action of selected microbial toxins in foods and feeds. Pohland AE, Dowell VR Jr, Richards JL, editors. New York: Plenum Press, pp. 91-102.
54. Holmes RK, Jobling MG, Connell TD (1995). Cholera toxin and related enterotoxins of Gram-negative bacteria. In: Handbook of natural toxins. Vol. 8. Bacterial toxins and virulence factors in disease. Moss J, Iglewski B, Vaughn M, Tu AT, editors. New York: Marcel Dekker, Inc., pp. 225-255.
55. Holmgren J, Lycke N, Czerkinsky C (1993). Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11:1179-1184.
56. Honma K, Kato T, Okuda K (1999). Salivary immunoglobulin A production against a synthetic oligopeptide antigen of Actinobacillus actinomycetemcomitans fimbriae. Oral Microbiol Immunol 14:288-292.
57. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CO (1994). Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol 152:4663-4670.
58. Itano AA, Jenkins MK (2003). Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 4:733-739.
59. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR (1993). Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant Infect Immun 61:4272-4279.
60. Jagusztyn-Krynicka EK, Clark-Curtiss JE, Curtiss R (1993). Escherichia coli heat-labile toxin subunit B fusions with Streptococcus sobrinus antigens expressed by Salmonella typhimurium oral vaccine strains: importance of the linker for antigenicity and biological activities of the hybrid proteins. Infect Immun 61:1004-1015.
61. Janeway CA, Medzhitov R (2002). Innate immune recognition. Annu Rev Immunol 20:197-216.
62. Jespersgaard C, Hajishengallis G, Greenway TE, Smith DJ, Russell MW, Michalek SM (1999). Functional and immunogenic characterization of two cloned regions of Streptococcus mutans glucosyltransferase-I. Infect Immun 67:810-816.
63. Jespersgaard C, Zhang P, Hajishengallis G, Russell MW, Michalek SM (2001). Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein. Infect Immun 69:6604-6611.
64. Jobling MG, Holmes RK (1992). Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras. Infect Immun 60:4915-4924.
65. Johansson E-L, Rask C, Fredriksson M, Eriksson K, Czerkinsky C, Holmgren J (1998). Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 66:514-520.
66. Katz J, Harmon CC, Buckner GP, Richardson GJ, Russell MW, Michalek SM (1993). Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin. Infect Immun 61:1964-1971.
67. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, et al. (2002). Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 169:566-574.
68. Lebens M, Sun J-B, Sadeghi H, Backstrom M, Olsson I, Mielcarek N, et al. (2003). A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. Vaccine 21:514-520.
69. Lencer WI, Tsai B (2003). The intracellular voyage of cholera toxin: going retro. Trends Biochem Sci 28:639-645.
70. Lencer WI, Constable C, Moe S, Jobling MG, Webb HM, Ruston S, et al. (1995). Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J Cell Biol 131:951-962.
71. Li TK, Fox BS (1996). Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokine production from a T cell clone. Int Immunol 8:1849-1856.
72. Li X, Erbe JL, Lockatell CV, Johnson DE, Jobling MG, Holmes RK, et al. (2004). Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infect Immun 72:7306-7310.
73. Liu YJ, Banchereau J (1997). Regulation of B-cell commitment to plasma cells or to memory B cells. Semin Immunol 9:235-240.
74. Lycke N, Lindholm L, Holmgren J (1983). IgA isotype restriction in the mucosal but not in the extramucosal immune response after oral immunizations with cholera toxin or cholera B subunit. Int Arch Allergy Appl Immunol 72:119-127.
75. Lycke N, Tsuji T, Holmgren J (1992). The adjuvant effect of Vibrio cholerae and E. coli heat labile enterotoxins is linked to the ability to stimulate cAMP. Eur J Immunol 22:2277-2281.
76. Maeyama J, Isaka M, Yasuda Y, Matano K, Kozuka S, Taniguchi T, et al. (2001). Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Microbiol Immunol 45:111-117.
77. Martin MH, Metzger DJ, Michalek SM, Connell TD, Russell MW (2000). Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins, LT-IIa and LT-IIb. Infect Immun 68:281-287.
78. + T cells. Infect Immun 69:252-261.
79. + T cells. Infect Immun 69:4486-4492.
80. Matousek MP, Nedrud JG, Harding CV (1996). Distinct effects of recombinant cholera toxin B subunit and holotoxin on different stages of class II MHC antigen processing and presentation by macrophages. J Immunol 156:4137-4145.
81. McKenzie SJ, Halsey JF (1984). Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 133:1818-1824.
82. Mekalanos JJ, Collier RJ, Romig WR (1979). Enzymic activity of cholera toxin. II. Relationships to proteolytic processing, disulfide bond reduction, and subunit composition. J Biol Chem 254:5855-5861.
83. Merritt EA, Sarfaty S, Van Den Akker F, L'Hoir C, Martial JA, Hol WGJ (1994). Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Prot Sci 3:166-175.
84. Mestecky J (1987). The common mucosal immune system and current strategies for induction of immune response in external secretions. J Clin Immunol 7:265-276.
85. Mestecky J, Moldoveanu Z, Michalek SM, Morrow C, Compans RW, Schafer DP, et al. (1997). Current options for vaccine delivery systems by mucosal routes. J Controlled Release 48:243-257.
86. Mestecky J, Bienenstock J, Lamm ME, Mayer L, Strober W, McGhee JR, editors (2005). Mucosal immunology. 3rd ed. San Diego: Academic Press/Elsevier.
87. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. (2004). Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350:896-903.
88. Nagai Y, Iwamori M (1984). Ganglioside distribution at different levels of organization and its biological implications. Adv Exp Med Biol 174:135-146.
89. Nagasawa T, Aramaki M, Talcamatsu N, Koseki T, Kobayashi H, Ishikawa I (1999). Oral administration of Porphyromonas gingivalis fimbriae with cholera toxin induces anti-fimbriae serum IgG, IgM, IgA and salivary IgA antibodies. J Periodontal Res 34:169-174.
90. Namikoshi J, Otake S, Maeba S, Hayakawa M, Abiko Y, Yamamoto M (2003). Specific antibodies induced by nasally administered 40-kDa outer membrane protein of Porphyromonas gingivalis inhibits coaggregation activity of P. gingivalis. Vaccine 22:250-256.
91. Nashar TO, Webb HM, Eaglestone S, Williams NA, Hirst TR (1996). Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc Natl Acad Sci USA 93:226-230.
92. Nashar TO, Hirst TR, Williams NA (1997). Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1. Immunology 91:572-578.
93. + T cells. Int Immunol 13:541-551.
94. Nawar HF, Arce S, Russell MW, Connell TD (2005). Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities. Infect Immun 73:1330-1342.
95. Ogra PL, Faden H, Welliver RC (2001). Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14:430-445.
96. Ogushi K-I, Wada A, Niidome T, Okuda T, Llanes R, Nakayama M, et al. (2004). Gangliosides act as co-receptors for Salmonella enteritidis FliC and promote FliC-induction of human β-defensin-2 expression in Caco-2 cells. J Biol Chem 279:12213-12219.
97. Orlandi PA, Critchley DR, Fishman PH (1994). The heat-labile enterotoxin of Escherichia coli binds to polylactosaminoglycan-containing receptors in CaCo-2 human intestinal epithelial cells. Biochemistry 33:12886-12895.
98. Parker DC (1993). T cell-dependent B cell activation. Annu Rev Immunol 11:331-360.
99. Paul WE, Seder RA (1994). Lymphocyte responses and cytokines. Cell 76:241-251.
100. Petrovska L, Lopes L, Simmons CP, Pizza M, Dougan G, Chain BM (2003). Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 21:1445-54.
101. Phipps PA, Stanford MR, Sun JB, Xiao BG, Holmgren J, Shinnick T, et al. (2003). Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur J Immunol 33:224-232.
102. Pickett CL, Twiddy EM, Belisle BW, Holmes RK (1986). Cloning of genes that encode a new heat-labile enterotoxin of Escherichia coli. J Bacteriol 165:348-352.
103. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, et al. (2001). Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541.
104. Plant A, Williams R, Jackson ME, Williams NA (2003). The B subunit of Escherichia coli heat labile enterotoxin abrogates oral tolerance, promoting predominantly Th2-type immune responses. Eur J Immunol 33:3186-3195.
105. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ (1997). Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 158:834-841.
106. Raghavan S, Svennerholm A-M, Holmgren J (2002). Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. Infect Immun 70:4621-4627.
107. Rask C, Fredriksson M, Lindblad M, Czerkinsky C, Holmgren J (2000a). Mucosal and sytemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant. APMIS 108:178-186.
108. Rask C, Holmgren J, Fredriksson M, Lindblad M, Nordström I, Sun JB, et al. (2000b). Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice. Clin Exp Allergy 30:1024-1032.
109. Rodighiero C, Aman AT, Kenny MJ, Moss J, Lencer WI, Hirst TR (1999). Structural basis for the differential toxicity of cholera toxin and Escherichia coli heat-labile enterotoxin. Construction of hybrid toxins identifies the A2-domain as the determinant of differential toxicity. J Biol Chem 274:3962-3969.
110. Russell MW (1992). Immunization against dental caries. Curr Opin Dent 2:72-80.
111. Russell MW (1998). Future strategies to control oral infections. In: Oral biology at the turn of the century: misconceptions, truths, challenges and prospects. Guggenheim B, Shapiro S, editors. Basel, Switzerland: S. Karger AG, pp. 239-246.
112. Russell MW (2003). Mucosal immunity. In: New bacterial vaccines. Ellis RW, Brodeur BR, editors. Georgetown, TX, and New York: Eurekah.com and Kluwer Academic/Plenum, pp. 63-79.
113. Russell MW, Sibley DA (1999). IgA as an anti-inflammatory regulator of immunity. Oral Dis 5:55-56.
114. Russell MW, Wu H-Y (1991). Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit. Infect Immun 59:4061-4070.
115. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM (1996). Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect Immun 64:1272-1283.
116. Russell MW, Hajishengallis G, Childers NK, Michalek SM (1999). Secretory immunity in defense against cariogenic mutans streptococci. Caries Res 33:4-15.
117. Russell MW, Childers NK, Michalek SM, Smith DJ, Taubman MA (2004). A caries vaccine? The state of the science of immunization against dental caries. Caries Res 38:230-235.
118. Ryan EJ, McNeela E, Pizza M, Rappuoli R, O'Neill L, Mills KHG (2000). Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol 165:5750-5759.
119. + T cells secreting Th1 or Th2 cytokines. Immunity 2:271-279.
120. Sanchez J, Svennerholm AM, Holmgren J (1988). Genetic fusion of a non-toxic heat-stable enterotoxin-related decapeptide-antigen to cholera toxin B subunit. FEBS Lett 241:110-114.
121. Shen XZ, Lagergård T, Yang YH, Lindblad M, Fredriksson M, Holmgren J (2001). Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization. Infect Immun 69:297-306.
122. Sheoran AS, Artiushin S, Timoney JF (2002). Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin. Vaccine 20:1653-1659.
123. Simmons CP, Ghaem-Magami M, Petrovska L, Lopes L, Chain BM, Williams NA, et al. (2001). Immunomodulation using bacterial enterotoxins. Scand J Immunol 53:218-226.
124. Smith DJ (2002). Dental caries vaccines: prospects and concerns. Crit Rev Oral Biol Med 13:335-349.
125. Smith DJ, King WF, Barnes LA, Trantolo D, Wise DL, Taubman MA (2001). Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines. Infect Immun 69:4767-4773.
126. Smith DJ, Lam A, Barnes LA, King WF, Peacock Z, Wise DL, et al. (2003). Remote glucosyltransferase-microparticle vaccine delivery induces protective immunity in the oral cavity. Oral Microbiol Immunol 18:240-248.
127. + T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner in vivo. J Immunol 165:3136-3144.
128. Sonnino S, Acquotti D, Riboni L, Giuliani A, Kirschner G, Tettamanti G (1986). New chemical trends in ganglioside research. Chem Phys Lipids 42:3-26.
129. Soong G, Reddy B, Sokol S, Adamo R, Prince A (2004). TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J Clin Invest 113:1482-1489.
130. Sultan F, Jin LL, Jobling MG, Holmes RK, Stanley SL (1998). Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin. Infect Immun 66:462-468.
131. Sun JB, Holmgren J, Czerkinsky C (1994). Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 91:10795-10799.
132. Sun J-B, Rask C, Olsson T, Holmgren J, Czerkinsky C (1996). Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 93:7196-7201.
133. Takahashi I, Okahashi N, Kanamoto T, Asakawa H, Koga T (1990). Intranasal immunization of mice with recombinant protein antigen of serotype c Streptococcus mutans and cholera toxin B subunit. Arch Oral Biol 35:475-477.
134. Takahashi I, Okahashi N, Matsushita K, Tokuda M, Kanamoto T, Munekata E, et al. (1991). Immunogenicity and protective effect against oral colonization by Streptococcus mutans of synthetic peptides of a streptococcal surface protein antigen. J Immunol 146:332-336.
135. Takamatsu-Matsushita N, Yamaguchi N, Kawasaki M, Yamashita Y, Takehara T, Koga T (1996). Immunogenicity of Actinobacillus actinomycetemcomitans serotype b-specific polysaccharide-protein conjugate. Oral Microbiol Immunol 11:220-225.
136. Takeda K, Kaisho T, Akira S (2003). Toll-like receptors. Annu Rev Immunol 21:335-376.
137. Tarkowski A, Sun JB, Holmdahl R, Holmgren J, Czerkinsky C (1999). Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthr Rheum 42:1628-1634.
138. Triantafilou M, Morath S, Mackie A, Hartung T, Triantafilou K (2004). Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipid rafts on the plasma membrane. J Cell Sci 117:4007-4014.
139. Truitt RL, Hanke C, Radke J, Mueller R, Barbieri JT (1998). Glycosphingolipids as novel targets for T-cell suppression by the B subunit of recombinant heat-labile enterotoxin. Infect Immun 66:1299-1308.
140. Turcanu V, Hirst TR, Williams NA (2002). Modulation of human monocytes by Escherichia coli heat-labile enterotoxin B-subunit: altered cytokine production and its functional consequences. Immunology 106:316-325.
141. Van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR (2000). Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165:4778-4782.
142. Van Loon FPL, Clemens JD, Chakraborty J, Rao MR, Kay BA, Sack DA, et al. (1996). Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14:162-166.
143. Verweij WR, De Haan L, Holtrop M, Agsteribbe E, Brands R, Van Scharrenburg GJM, et al. (1998). Musosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 16:2069-2076.
144. Waldo FB, van den Wall Bake AWL, Mestecky J, Husby S (1994). Suppression of the immune response by nasal immunization. Clin Immunol Immunopathol 72:30-34.
145. Wang J, Li L, Zheng J, Yu J, Yang X, Geng Y, et al. (2003). Highly efficient expression, purification of recombinant LTB protein and its activity against mucosal immunoadjuvant by nasal immunization. Chin Med J 116:1115-1117.
146. Williams NA, Hirst TR, Nashar TO (1999). Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol Today 20:95-101.
147. Wilson AD, Clarke CJ, Stokes CR (1990). Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand J Immunol 31:443-451.
148. Wilson AD, Robinson A, Irons L, Stokes CR (1993). Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen. Vaccine 11:113-118.
149. Wu H-Y, Russell MW (1993). Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun 61:314-322.
150. Wu H-Y, Russell MW (1998). Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine 16:286-292.
151. Wu H-Y, Abdu S, Stinson D, Russell MW (2000). Generation of female genital tract antibody responses by local or central (common) mucosal immunization. Infect Immun 68:5539-5545.
152. Yamada KM, Critchley DR, Fishman PH, Moss J (1983). Exogenous
153. Yamamoto M, Kiyono H, Yamamoto S, Batanero E, Kweon MN, Otake S, et al. (1999). Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J Immunol 162:7015-7021.
154. Yanagita M, Hiroi T, Kitagaki N, Hamada S, Ito H, Shimauchi H, et al. (1999). Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J Immunol 162:3559-3565.
155. Yokomizo Y, Watanabe F, Imada Y, Inumaru S, Yanaka T, Tsuji T (2002). Mucosal immunoadjuvant activity of the low toxic recombinant Escherichia coli heat-labile enterotoxin produced by Bacillus brevis for the bacterial subunit or component vaccine in pigs and cattle. Vet Immunol Immunopathol 87:291-300.
156. Zhang P, Yang QB, Balkovetz DF, Lewis JP, Clements JD, Michalek SM, et al. (2005). Effectiveness of the B subunit of cholera toxin in potentiating immune responses to the recombinant hemagglutinin/adhesin domain of the gingipain Kgp from Porphyromonas gingivalis. Vaccine 23:4734-4744.